News from immungene, inc

Nov 07, 2013, 05:00 ET

ImmunGene Raises $9 Million in Series A Financing

 ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced...

Jun 03, 2013, 22:26 ET

ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein

ImmunGene, Inc. today announced that pre‑clinical studies of its novel anti‑CD20 antibody-interferon alpha fusion protein, IGN002, demonstrated...

Feb 11, 2011, 05:00 ET

ImmunGene's Interferon Payload Technology Platform Featured in BioCentury Magazine

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today that a profile of the company...

Jan 05, 2011, 05:15 ET

ImmunGene Announces Multi-Target R&D Collaboration With Cephalon Australia for Interferon Payload Technology

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics, announced today it has entered into a...

Nov 22, 2010, 05:30 ET

ImmunGene Receives $244,479 Grant Under the Patient Protection and Affordable Care Program for Its Anti-Cancer Technology

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into...

Nov 11, 2010, 05:30 ET

ImmunGene's Pipeline of Next Generation Cancer Therapeutics Featured in BioWorld Today

ImmunGene, Inc., a privately held drug development company focused on targeted antibody therapeutics with numerous anti-cancer functions built into...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

Research and Markets
Analysts Review
ReportBuyer